Prof. Mustafa Aziz Hatiboğlu is a practicing neurosurgeon and translational neuro-oncology researcher, specializing in the study of chemo- and radio-resistance in gliomas, glioma stem cells, and innovative therapeutic approaches. His work spans from molecular mechanisms of treatment resistance to clinical innovations such as Gamma Knife radiosurgery. As director of BILSAB's brain tumor biobank initiative, he is building a critical resource for advancing precision medicine in neuro-oncology.
Prof. Hatiboğlu's research addresses some of the most formidable challenges in brain cancer, particularly glioblastoma—the most aggressive and treatment-resistant primary brain tumor. His studies have investigated the role of autophagy and glioma stem cells in driving therapy resistance, identified genetic alterations linked to rapidly progressive glioblastoma, and explored the potential of natural compounds like thymoquinone in inducing apoptosis and reducing tumor survival pathways. He has also contributed to pioneering work in nanomedicine and liposome-based drug delivery strategies, which aim to overcome the blood-brain barrier and enhance therapeutic efficacy.
Beyond glioblastoma, his clinical research includes investigations of rare tumor subtypes such as sclerosing meningioma, where he has applied novel immunohistochemical markers for diagnosis and grading. His translational efforts extend into the realm of radiosurgery, where he has demonstrated how Gamma Knife treatment can modulate microRNA expression in patients with brain metastases, revealing new avenues for immune and molecular response modulation. Through these combined clinical and laboratory initiatives, Prof. Hatiboğlu is shaping the future of neuro-oncology with a vision that integrates surgery, molecular biology, and next-generation therapeutics.
Click here for the Avasis link
Click here for the Hatiboğlu Lab
